Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05011097 Org: User:
Start: 07/08/21 End: 12/30/24 Due: 12/30/25

A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04501770 Org: User:
Start: 08/28/21 End: 12/31/23 Due: 12/31/24

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05028556 Org: User:
Start: 08/06/21 End: 08/06/24 Due: 08/06/25

A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06266143 Org: User:
Start: 02/08/23 End: 12/31/24 Due: 12/31/25

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Phase: N/A Priority: Normal
NCT ID: NCT06266091 Org: User:
Start: 11/24/21 End: 12/31/24 Due: 12/31/25

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Phase: N/A Priority: Normal
NCT ID: NCT06432296 Org: User:
Start: 03/20/24 End: 11/11/25 Due: 11/11/26

A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05543330 Org: User:
Start: 09/30/22 End: 12/01/24 Due: 12/01/25

A Study of M701 (EpCAM and CD3) in Malignant Ascites

Phase: N/A Priority: Normal
NCT ID: NCT04501744 Org: User:
Start: 10/30/18 End: 06/30/21 Due: 06/30/22